Immunome, Inc. · NASDAQ:IMNM
Immunome — Investor Presentation (October 2021)
34 slides from Immunome's investor presentation, Oct 18, 2021
Slide 1: Harnessing the Human Memory B Cell Response To Develop Antibody-Based Therapeutics
Harnessing the Human Memory B Cell Response To Develop Antibody - Based Therapeutics October 15, 2021 Immunome, Inc. 665 Stockton Drive, Suite 300 | Exton, PA 19341 610.321.3700 | www.immunome.com Copyright © 2021 Immunome, Inc. All rights reserved.
Slide 2: Disclaimers and Forward-Looking Statements
2 Disclaimers and Forward - Looking Statements This presentation includes certain disclosures that contain “forward - looking statements” intended to qualify for the “safe harbor” from liability established by the Private Securities Litigation Reform Act of 1995, as amended, including, without limit
Slide 3: Experienced Management Team
Experienced Management Team Copyright © 2021 Immunome, Inc. All rights reserved. 3 Purnanand Sarma, PhD President & CEO Corleen Roche Chief Financial Officer Mike Morin, PhD Chief Scientist Sandra Stoneman, Esq. Chief Legal Officer Dennis Giesing, PhD Chief Development Officer Matthew Robinson, PhD
Slide 4: Immunome At A Glance
IMM - BCP - 01 Treatment of COVID - 19 • Three antibody cocktail • Binds to three non - overlapping regions of the spike protein • ACE2 and Non ACE2 dependent neutralization • Potent Effector Function – potential for viral clearance 4 Copyright © 2021 Immunome, Inc. All rights reserved. IMM - ONC -
Slide 5: Immunome Development Pipeline and Anticipated Key Milestones
Immunome Development Pipeline and Anticipated Key Milestones ANTI - INFECTIVES TARGET PRODUCT CANDIDATE DESCRIPTION DISCOVERY PRECLINICAL ANTICIPATED MILESTONE IMM - BCP - 01 Three SARS - CoV - 2 Epitopes Three antibody cocktail IND filing Q4 2021 ONCOLOGY TARGET PRODUCT CANDIDATE DESCRIPTION DISCOV
Slide 6: Proprietary Discovery Engine
6 Copyright © 2021 Immunome, Inc. All rights reserved. Proprietary Discovery Engine Memory B cells: The Most Educated Components of Human Immune System We see Disease Through the Lens of a B cell Antibody Screening Deep, multiplexed interrogation of patient memory B cell responses Patient Response C
Slide 7: Infectious Diseases Collaboration with U.S. DoD awarded up to $17.6M in funding
Infectious Diseases Copyright © 2021 Immunome, Inc. All rights reserved. Collaboration with U.S. DoD awarded up to $17.6M in funding
Slide 8: COVID-19 Summary
COVID - Summary Current COVID Vaccines and Antibody Therapeutics Not Sufficient • Breakthrough infections despite vaccine use 1 • FDA Emergency Use Authorization of antibody therapeutics for treatment of mild to moderate COVID - 19 2 • First - generation antibody therapeutics developed based on viru
Slide 9: COVID-19 Vaccines Are Effective, But Not Sufficient
COVID - 19 Vaccines Are Effective, But Not Sufficient 9 COVID - 19 Vaccines Are Effective, But Not Sufficient Copyright © 2021 Immunome, Inc. All rights reserved. COVID - 19 Will Likely Remain Endemic & Specific Populations Will Continue to be at Risk COVID surges despite ~48% of the world populatio
Slide 10: Emerging Variants Evading Antibodies Against Immunodominant Epitopes
COVID - 19 Vaccines Are Effective, But Not Sufficient Emerging Variants Evading Antibodies Against Immunodominant Epitopes Copyright © 2021 Immunome, Inc. All rights reserved. 10 Pfizer Vaccine AstraZeneca Vaccine ED50 = Neutralization titer Planas et al Nature 596, 276 - 280 (2021) https://doi.org/
Slide 11: COVID-19 Therapeutics Will Remain Critical
COVID - 19 Therapeutics Will Remain Critical Variants will likely continue to emerge, and may rapidly change the landscape » Delta variant encompasses >99% of all U.S. cases since discovery in April ‘21 » CDC monitoring 10 additional variants with substitutions of concern, including Eta, Iota, Kappa
Slide 12: Three Antibody Cocktail has Multiple Points of Attack and Mechanisms of Action
Three Antibody Cocktail has Multiple Points of Attack and Multiple Mechanisms of Action » Plateau of clinical benefit with escalated dose Based on our current beliefs/opinions about selected publicly available preclinical data for other products and programs relative to IMM - BCP - 01 IMM - BCP - 01
Slide 13: IMM-BCP-01: Mimics the Body's Natural Response
IMM - BCP - 01: Mimics the Body’s Natural Response Leverages Unique and Cryptic Epitopes EPITOPE 1: IMM20253 (Non - ACE2 Dependent) • Broadly conserved across all SARS - CoV - 2 strains and other Beta coronaviruses • Novel mechanism. Antibody exhibits non ACE2 dependent neutralization EPITOPE 2: IMM
Slide 14: IMM-BCP-01 Interferes with Viral Life Cycle Utilizing Different Mechanisms
IMM - BCP - 01 Interferes with Viral Life Cycle Utilizing Different Mechanisms Pre - fusion spike (S1 + S2) Post - fusion spike (S2) ACE2 BLOCKADE NON ACE2 DEPENDENT NEUTRALIZATION ACE2 1 2 IMM20253 IMM20190 + IMM20184 NORMAL VIRAL FUSION INTO CELL PRE - FUSION CONFORMATION CELL MEMBRANE VIRAL MEMBR
Slide 15: IMM-BCP-01: Superior Preclinical Efficacy vs Sotrovimab
Sotrovimab (EUA Approved at 500 mg Dose) IMM - BCP - 01 15 Superior Preclinical Efficacy vs Sotrovimab Copyright © 2021 Immunome, Inc. All rights reserved. Cathcart , A.L et al BioRxiv 2021.03.09.434607 WT Strain • Prophylactic setting (Day - 2) in infected hamsters • ~ 1.5 - log clearance at 5mg/kg
Slide 16: IMM-BCP-01 Neutralizes All Current and Former CDC Variants of Concern
Copyright © 2021 Immunome, Inc. All rights reserved. 16 IMM - BCP - 01 Neutralizes All Current and Former CDC Variants of Concern in Pseudovirus Testing Alpha, Beta, Gamma, Delta » Current and former CDC Variants of Concern (as of 10/12/2021) Emerging Variants » Lambda, Mu US and European reference
Slide 17: Viral Clearance is Important, Especially in Immunocompromised Patients
17 Viral Clearance is Important, Especially in Immunocompromised Patients Copyright © 2021 Immunome, Inc. All rights reserved. Immunocompromised patients exhibit prolonged viral load Caillard , S., Benotmane , I., Vargas, G. G., Perrin, P., & Fafi - Kremer, S. (2021). SARS - CoV - 2 viral dynamics i
Slide 18: Viral Clearance is Important: Prolonged Infection Leads to Resistant Variants
18 Viral Clearance is Important, Especially in Immunocompromised Patients Copyright © 2021 Immunome, Inc. All rights reserved. Prolonged infection leads to emerging resistant variants Caillard , S., Benotmane , I., Vargas, G. G., Perrin, P., & Fafi - Kremer, S. (2021). SARS - CoV - 2 viral dynamics
Slide 19: IMM-BCP-01 Clinical Development Plan
3 5 IND Filing Q4 2021 Phase 1b FIP Study Dose Ranging • Placebo - controlled • Safety, PK, Immunogenicity Potential Phase 1b Extension in Special Population • Treatment and prophylaxis • Safety, PK, viral load Phase 2 Potential Registration Study H2 2022 Copyright © 2021 Immunome, Inc. All rights r
Slide 20: Immunome's Approach Optimized for Ideal Target Profile
Immunome’s Approach Optimized for Ideal Target Profile • Preclinical potency suggests efficacious dose may allow for non - Intravenous dosing • Preclinical evidence of ACE dependent and non - dependent action; three different epitopes. Synergy against variants of concern. Clearance by phagocytosis a
Slide 21: COVID Antibody Market
COVID Antibody Market REGENERON $2.6B IN 2Q 2021 ADAGIO $3 - 4B ANALYST PROJECTED PEAK SALES * Addressable Patients • High Risk Vaccinated Patients with Breakthrough Infection • High Risk Unvaccinated Patients • Immunocompromised Patients (~9M in the US), Including: » Transplant » HIV » Chemotherapy
Slide 22: Oncology
Oncology • RESEARCH & DEVELOPMENT Copyright © 2021 Immunome, Inc. All rights reserved.
Slide 23: Oncology Summary
Oncology - Summary Highly disruptive platform discovering novel targets based on function - based interrogation of patient memory B - cell response to tumors • Broad, deep and unbiased interrogation • Operating at industrial scale; ~1300 hits, >50 novel targets/antibodies to - date • Platform highli
Slide 24: Novel Targets: Antibodies From Patient Memory B-cells Reveal Novel Therapeutic Targets
Novel Targets Antibodies From Patient Memory B - cells Reveal Novel Therapeutic Targets Tumor Tumor killing Tumor Antigen Immune Response Antibody Control Exosome T cells activation Angiogenesis Metabolism Recruitment Mutation Post - translational modification Mis - localization Oncovirus Myeloid ce
Slide 25: Novel Insights from Discovery Engine
25 Novel Insights from Discovery Engine 1. Adv Clin Chem. 2016;74:103 - 41.DOI: 10.1016/bs.acc.2015.12.005 2. Mol Cancer. 2019 Oct 23;18(1):146. doi : 10.1186/s12943 - 019 - 1074 - 3 3. Including some commercially - validated targets such as ERBB2 Provides Critical Insights Into Cancer Biology Such
Slide 26: Immunome Oncology R&D Pipeline
Immunome Oncology R&D Pipeline Targets Identified From Patient Antibodies Program Novel Immune Modulators Potential Cancers of Relevance Stage/Format IMM - ONC - 01 (Anti - IL - 38) Neutralize apoptotic tumor cells derived IL - 38; recruit and activate immune cells Lung, head and neck, melanoma, and
Slide 27: IL-38: A Novel Oncology Target
IL - 38: A Novel Oncology Target IL - 38 Dampens Innate Anti - Tumor Immunity • IL - 38 is an IL - 1 cytokine family member, but most closely resembles the natural antagonists of the family (IL - 1Ra and IL - 36a) ANTAGONISTS AGONISTS IL36 a IL36 b IL36 g IL36Ra IL38 Autoimmunity Immune Suppression
Slide 28: IL-38 Dampens Innate Anti-Tumor Immunity: Immunome Data
• IL - 38 secretion associated with apoptotic cell death 1 • Acts during tissue damage to limit unwanted immune activation 2 • Tumor cells secrete IL - 38 during apoptosis in vitro • Rational combination with chemotherapies that induce apoptosis in tumors Tumor cells secrete IL - 38 upon apoptosis i
Slide 29: IL-38 is Expressed in Multiple Tumors of High Unmet Medical Need
IL - 38 is Expressed in Multiple Tumors of High Unmet Medical Need Immunome Data – Directly Confirms IL - 38 Expression in Primary Patient Tumors by IHC IL - 38 Expression in Solid Tumors IL - 38 is expressed in Multiple Tumors of High Unmet Medical Need Head & Neck Lung, Squamous Esophagus Cervix P
Slide 30: IL-38 Overexpression Inhibits Infiltration of T cells into Tumors
IL - 38 Overexpression Inhibits Infiltration of T cells into Tumors In Vivo High IL - 38 Expression is Associated with Reduced Immune Cell Infiltration IL - 38 Expression in Solid Tumors IL - 38 is Associated with Reduced Immune Cell Infiltration Immunome analysis of the Cancer Genome Atlas (TCGA) d
Slide 31: Blocking IL-38 Leads to Tumor Control in Two Different Tumor Models
Demonstration of Anti - Tumor Activity (B16F10 Model) Induction of Anti - Tumor Memory (EMT6 Model) • Immunologically cold tumor model • IMM - ONC - 01 significantly inhibits B16.F10 tumor growth in vivo at 10 or 50 mg/Kg doses • ~40% response rate upon treatment with IMM - ONC - 01 • Animals with c
Slide 32: IMM-ONC-01 Program Summary
• IL - 38 is a novel checkpoint in the innate immune system • Targeting IL - 38 using IMM - ONC - 01 expected to boost anti - tumor immunity • Preclinical research confirms the mechanism of action, and demonstrates efficacy, even as a monotherapy » Potential indications include lung, head and neck,
Slide 33: Immunome At A Glance
IMM - BCP - 01 Treatment of COVID - 19 • Three antibody cocktail • Binds to three non - overlapping regions of the spike protein • ACE2 and Non ACE2 dependent neutralization • Potent Effector Function – potential for viral clearance 33 Copyright © 2021 Immunome, Inc. All rights reserved. IMM - ONC -
Slide 34: Thank You
Thank You Immunome, Inc. 665 Stockton Drive, Suite 300 | Exton, PA 19341 610.321.3700 | www.immunome.com